Edwards Lifesciences CorpEW
| Dec 31,
2010 | Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income | 218 | - | - | - | - | - | - | - | - | - | - | - | - | 1,399 | 4,170 |
|---|
| Depreciation and amortization | 57 | 58 | 57 | 69 | 69 | 66 | 71 | 82 | 77 | 89 | 107 | 135 | 140 | 145 | 155 |
|---|
| Non-cash operating lease cost | - | - | - | - | - | - | - | - | - | - | - | - | 27 | 28 | 28 |
|---|
| Stock-based compensation (Notes 2 and 16) | 29 | 35 | 42 | 47 | 48 | 50 | 57 | 62 | 71 | 81 | 93 | 109 | 127 | 139 | 162 |
|---|
| Gain on sale of product group (Note 5) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,348 |
|---|
| Asset Impairment Charges | - | - | - | - | - | - | - | - | - | - | - | - | 55 | - | - |
|---|
| Change in fair value of contingent consideration liabilities (Note 13) | - | - | - | - | - | - | - | -10 | -6 | -6 | 14 | -124 | -36 | -26 | - |
|---|
| (Gain) loss on investments, net | - | - | - | - | - | - | - | - | - | - | - | - | -51 | -0 | 5 |
|---|
| Deferred income taxes | 11 | 1 | -8 | -0 | 71 | 95 | 37 | -18 | 27 | -12 | 49 | 41 | 255 | 272 | 323 |
|---|
| Gain on remeasurement of previously held equity interest upon acquisition (Note 10) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55 |
|---|
| Other | - | 1 | -4 | -3 | -14 | -11 | -8 | 6 | -13 | 3 | 4 | 23 | -8 | -8 | -18 |
|---|
| Accounts and other receivables, net | 34 | 54 | 27 | -8 | 27 | 38 | 57 | 4 | 29 | 88 | -42 | 91 | 84 | 141 | -121 |
|---|
| Inventories | 37 | 57 | 22 | 44 | 31 | 68 | 66 | 124 | 66 | 105 | 121 | -19 | 213 | 289 | 256 |
|---|
| Prepaid expenses and other current assets | 3 | -21 | -13 | -5 | 1 | 0 | 13 | 10 | -16 | 7 | 29 | -8 | -0 | 82 | -23 |
|---|
| Accounts payable and accrued liabilities | 64 | 62 | 42 | 50 | 113 | 29 | 74 | 85 | 193 | -63 | -84 | 195 | -21 | 146 | 90 |
|---|
| Intellectual property agreement accrual | - | - | - | - | - | - | - | - | - | - | 271 | -29 | -45 | -33 | -37 |
|---|
| Income taxes | - | - | - | - | 128 | 135 | 105 | 278 | -158 | 43 | -53 | 62 | -6 | -6 | -187 |
|---|
| Long-term prepaid royalties (Note 3) | - | - | - | - | - | - | - | - | - | - | - | - | - | 110 | -8 |
|---|
| Other | -9 | 1 | -5 | -2 | -7 | -7 | -22 | -8 | -1 | -16 | -16 | 19 | 52 | 12 | 21 |
|---|
| Net cash provided by operating activities | 251 | - | - | - | - | - | - | 1,001 | 927 | 1,179 | 1,054 | 1,732 | 1,218 | 896 | 542 |
|---|
| Capital expenditures | 62 | 83 | 121 | 109 | 83 | 103 | 176 | 168 | 239 | 254 | 407 | 326 | 245 | 253 | 252 |
|---|
| Purchases of held-to-maturity investments (Note 8) | - | - | - | - | 1,956 | 929 | 595 | 805 | 210 | 130 | 162 | 250 | 354 | 66 | 46 |
|---|
| Proceeds from Sale and Maturity of Held-to-Maturity Securities | - | - | - | - | 1,611 | 1,260 | 853 | 655 | 578 | 50 | 212 | 138 | 420 | 98 | 58 |
|---|
| Purchases of available-for-sale investments (Note 8) | - | - | - | - | - | - | - | - | 249 | 438 | 690 | 1,629 | 316 | 9 | 900 |
|---|
| Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale | - | - | - | - | 2 | 180 | 233 | 449 | 223 | 360 | 565 | 391 | 940 | 618 | 800 |
|---|
| Business combinations, net of cash (Note 10) | - | - | - | - | - | - | - | - | - | - | - | - | - | 95 | 1,062 |
|---|
| Payments for acquisition options (Note 9) | - | - | - | - | - | - | - | - | - | 35 | 10 | 13 | 110 | 30 | 46 |
|---|
| Issuances of notes receivable | - | - | - | - | - | - | - | - | - | - | - | - | - | 63 | 63 |
|---|
| Collections of notes receivable | - | - | - | - | - | - | - | - | - | - | - | 20 | 18 | - | - |
|---|
| Investments in intangible assets | 1 | 8 | 7 | 1 | 11 | 4 | 41 | 7 | 3 | 24 | 0 | 4 | 20 | 13 | 30 |
|---|
| Proceeds from sale of product group | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,927 |
|---|
| Other | - | - | -1 | 4 | - | - | 1 | -1 | -5 | 24 | 12 | 44 | 29 | 13 | 73 |
|---|
| Net cash provided by investing activities | -61 | - | - | - | - | - | - | -647 | 77 | -596 | -531 | -1,722 | 252 | 174 | 2,313 |
|---|
| Purchases of treasury stock | 200 | 303 | 344 | 497 | 301 | 280 | 662 | 763 | 796 | 263 | 625 | 513 | 1,727 | 880 | 1,159 |
|---|
| Proceeds from stock plans | 92 | 60 | 100 | 46 | 113 | 87 | 103 | 114 | 147 | 161 | 141 | 159 | 146 | 170 | 180 |
|---|
| Other | -3 | -2 | 2 | 3 | -2 | -9 | 4 | - | -0 | -3 | -1 | -0 | -4 | -1 | -3 |
|---|
| Net cash used in financing activities | -104 | - | - | - | - | - | - | -473 | -1,101 | -116 | -487 | -356 | -1,584 | -711 | -983 |
|---|
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | - | - | -3 | -20 | 14 | 19 | 17 | 39 |
|---|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | - | - | 465 | 16 | -333 | -95 | 375 | 1,911 |
|---|